ICI. Prins - Can

I. Prins - Can

*This is an algorithmically generated author record based on publicly available information.

I. Prins - Can has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Anya Lissina

    Faculty of Health Sciences, University of Bristol , Bristol

    1 shared publication
  • Bethan Davies

    Division of Cancer and Genetics, School of Medicine, Cardiff University , Cardiff

    1 shared publication
  • C. G. Vermeij

    Department of Nephrology, Deventer Teaching Hospital, Nico, Deventer, The Netherlands

    1 shared publication
  • David Anthony Price

    Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK

    1 shared publication
  • David K. Cole

    Division of Infection and Immunity, School of Medicine, Cardiff University , Cardiff

    1 shared publication
  • Deborah L. Cross

    Division of Cancer and Genetics, School of Medicine, Cardiff University , Cardiff

    1 shared publication

Latest Publications

  • Assessing the binding interaction of polystyrene sulfonate with amitriptyline in healthy volunteers: a cross-over design — The BIND study

    by I. Prins - Can, I. R. F. van Berlo - van de Laar, M. Zeeman, C. G. Vermeij, E. van ’t Riet, K. Taxis, F. G. A. Jansman

    Purpose Polystyrene sulfonate is used for binding potassium in patients with chronic kidney disease (CKD). Because of its binding properties, it can potentially bind other medications and thereby decrease their bioavailability and effectiveness. Amitriptyline, often used by CKD patients for neuropathic pain, shows significant binding to polystyrene sulfonate in vitro. The purpose of this study was to determine the effect of polystyrene sulfonate on the exposure of amitriptyline in vivo when taken concomitantly in healthy volunteers. Methods We performed a prospective cross-over study in nine healthy volunteers. Participants were 18 years of age or older, did not use any medication, and had no known allergy to amitriptyline or polystyrene sulfonate. Participants visited Deventer Teaching Hospital twice. Once they received a single dose of amitriptyline 50 mg and once they received a single dose of both polystyrene sulfonate 15 g and amitriptyline 50 mg taken concomitantly, with a wash out period of at least 1 week. After intake of the medication, six blood samples were collected, at 2, 3, 4, 5, 6, and 8 h. Blood samples were analysed to determine maximum concentration (Cmax) and area under the curve 0–8 h after intake (AUC0–8 h). Difference in Cmax and AUC0–8 h was analysed with a paired T-test or Wilcoxon signed rank test, depending on normality of the data. A p-value < 0.05 was considered statistically significant. Results Of the nine participants included, eight participants completed both visits to the hospital. Mean maximum concentration (Cmax) of amitriptyline was 35.61 µg l−1 (95% CI 27.90–43.33 µg l−1) when taken alone, compared to 9.25 µg l−1 (95% CI 6.59–11.92 µg l−1) when taken with polystyrene sulfonate (p < 0.001). Mean AUC0–8 h of amitriptyline was 168.20 µg × h l−1 (95% CI 139.95–196.45 µg × h l−1) when taken alone and 45.78 µg × h l−1 (95% CI 30.20–61.36 µg × h l−1) when taken with polystyrene sulfonate (p < 0.0001). Conclusion These results show a significant decrease in exposure of amitriptyline of approximately 75% when taken concomitantly with polystyrene sulfonate, thereby probably compromising therapy efficacy. Patients using both amitriptyline and polystyrene sulfonate should be informed to separate intake of these medications. Trial registration NL8539 (17 April 2020).


  • Open Access

    Synthetic Peptides with Inadvertent Chemical Modifications Can Activate Potentially Autoreactive T Cells

    by Stephen Man, James E Redman, Deborah L. Cross, David K. Cole, Ilona Can, Bethan Davies, Shaikh Shimaz Hashimdeen, Reiss Reid, Sian Llewellyn-Lacey, Kelly L. Miners, et al.

    The human CD8+ T cell clone 6C5 has previously been shown to recognize the tert-butyl-modified Bax161–170 peptide LLSY(3-tBu)FGTPT presented by HLA-A*02:01. This nonnatural epitope was likely created as a by-product of fluorenylmethoxycarbonyl protecting group peptide synthesis and bound poorly to HLA-A*02:01. In this study, we used a systematic approach to identify and characterize natural ligands for the 6C5 TCR. Functional analyses revealed that 6C5 T cells only recognized the LLSYFGTPT peptide when tBu was added to the tyrosine residue and did not recognize the LLSYFGTPT peptide modified with larger (di-tBu) or smaller chemical groups (Me). Combinatorial peptide library screening further showed that 6C5 T cells recognized a series of self-derived peptides with dissimilar amino acid sequences to LLSY(3-tBu)FGTPT. Structural studies of LLSY(3-tBu)FGTPT and two other activating nonamers (IIGWMWIPV and LLGWVFAQV) in complex with HLA-A*02:01 demonstrated similar overall peptide conformations and highlighted the importance of the position (P) 4 residue for T cell recognition, particularly the capacity of the bulky amino acid tryptophan to substitute for the tBu-modified tyrosine residue in conjunction with other changes at P5 and P6. Collectively, these results indicated that chemical modifications directly altered the immunogenicity of a synthetic peptide via molecular mimicry, leading to the inadvertent activation of a T cell clone with unexpected and potentially autoreactive specificities.